Patient recruitment is a complex and dynamic part of clinical trial management, requiring proactive strategies, collaborations, and innovation to overcome challenges and achieve enrollment targets. Patient recruitment is vital for clinical trials, yet it presents challenges that impact study timelines, costs, and overall success. By adopting patient-centric approaches, using technology, and fostering collaborations across stakeholders, organizations can enhance recruitment efficiencies and accelerate study timelines, ultimately introducing new treatments to market faster for patients’ benefit worldwide. Patient recruitment in clinical trials will evolve due to technology advances, changing regulatory landscapes, and dynamic patient expectations. Outsourcing patient recruitment to specialized firms offers enterprises and Contract Research Organizations (CROs) opportunities to use expertise, scalability, and flexibility in navigating enrollment complexities. In this report, we examine the patient recruitment landscape, including the challenges that sponsors face. The report also assesses the current state of the supplier ecosystem and explores technology’s role in solving major challenges in patient recruitment. Scope Industry: life sciences Geography: global Services: life sciences BPS, life sciences ITS, and clinical development technology Contents In this report, we: Examine the patient recruitment landscape, including the challenges that sponsors face The report also assesses the current state of the supplier ecosystem and explores technology’s role in solving major challenges in patient recruitment Membership(s) Life Sciences Business Process Sourcing and Vendor Management

The evolving regulatory landscape poses significant challenges for life sciences enterprises. Enterprises struggle to navigate complex compliance frameworks, stay updated with emerging regulations, and manage diverse geographical requirements, all vital for achieving regulatory compliance and securing market access. As a result, enterprises are seeking providers with specialized knowledge and technology expertise to efficiently manage these intricate regulatory landscapes. In response, providers are enhancing their capabilities and offerings by investing significantly in technology. They are expanding their portfolios to include innovate tools and platforms to streamline regulatory processes. Additionally, to provide enhanced value and accessibility, providers are increasing their global presence by establishing localized support networks to cater to the nuanced requirements of diverse markets. In this report, we assess 20 providers featured on the Regulatory and Medical Affairs Operations PEAK Matrix®. Each profile offers a comprehensive picture of the provider’s key strengths and limitations. Scope Industry: life sciences Geography: global This report is based on Everest Group’s annual RFI process for calendar year 2024, interactions with leading regulatory and medical affairs providers, client reference checks, and an ongoing analysis of the regulatory and medical affairs Business Process Services (BPS) market Contents In this report, we: Position the providers on Everest Group’s PEAK Matrix® as Leaders, Major Contenders, and Aspirants Compare providers’ capabilities and market shares Assess providers’ key strengths and limitations Membership(s) Life Sciences Business Process Sourcing and Vendor Management

Healthcare organizations use Revenue Cycle Management (RCM) to manage the administrative and clinical functions related to processing claims, receiving payments, and generating revenue. The cycle begins with a patient scheduling an appointment and continues until the final payment is received. Due to increasing staff burnout cases, changing regulations, rising costs, and prioritizing improved patient experiences, there is a growing demand for third-party services to assist healthcare providers with their RCM operations. This has led to significant growth in the RCM services market, making it one of the fastest-growing segments in the healthcare industry. Within RCM, managed services and technology products are two key solution types. Both play vital roles in optimizing healthcare financial processes and have unique advantages. In this viewpoint, we explore the collaborative relationship between healthcare enterprises and RCM service providers, particularly examining the contributions of these two partnership models (technology products and managed services). The report examines how these models address challenges and looks ahead to future-proofing RCM in the ever-evolving healthcare landscape. Scope Industry: RCM Geography: global The assessment is based on Everest Group’s proprietary research and transactional intelligence Membership(s) Healthcare Payer and Provider Information Technology Healthcare Payer and Provider Business Process Sourcing and Vendor Management

Over the past year, enterprises have faced significant macroeconomic and geopolitical challenges. The potential uncertainties surrounding the implementation of the Inflation Reduction Act (IRA), the escalation in federal interest rates aimed at curbing inflation, and the ongoing conflicts leading to the relocation of clinical trials from regions such as Russia and Ukraine, have prompted enterprises to reassess their strategies. Moreover, the introduction of generative AI technologies, such as ChatGPT, empowers biopharmaceutical and MedTech companies to revamp their offerings and deliver state-of-the-art technology and cost efficiencies. In response to enterprises’ evolving demands, providers are enhancing their capabilities across the life sciences operations value chain. They have directed investments into various avenues, including Decentralized Clinical Trials (DCT), with numerous IT / Business Process Outsourcing (BPO) firms forging partnerships with DCT providers. Furthermore, additional investments encompass analytics-driven tools for precision Healthcare Professional (HCP) profiling and targeting, as well as the adoption of automation tools in areas such as Adverse Events (AE) intake to swiftly adapt to market demands. In this report, we assess 28 life sciences operations service providers featured on the life sciences operations PEAK Matrix®. The study will enable life sciences enterprises to identify suitable providers to transform their business processes and differentiate themselves. Scope Industry: life sciences business process services Geography: global The assessment is based on Everest Group’s annual RFI process for the calendar year 2023, interactions with leading life sciences operations service providers, client reference checks, and an ongoing analysis of the life sciences operations market Contents In this report, we: Examine 28 life sciences operations service providers featured on the life sciences operations PEAK Matrix® Assess providers’ capabilities and market shares Membership(s) Life Sciences Business Process Outsourcing Excellence

Over the past one year, enterprises had to overcome a series of macroeconomic and geopolitical challenges. The potential uncertainties with the implementation of the Inflation Regulation Act (IRA), and the rise in federal interest rates to curb inflation, compounded by an ongoing war resulting in shifting of clinical trials from Russia and Ukraine, have forced enterprises to rethink their strategies. Further, the advent of generative AI such as ChatGPT will enable the biopharma and MedTech firms to repackage their offerings and provide cutting-edge technology and cost optimization. To effectively serve the evolving enterprise needs, service providers have invested in increasing the breadth and depth of their functionalities/offerings across the life sciences operations value chain. They have invested in a host of avenues such as Decentralized Clinical Trials (DCT), with many Information Technology / Business Process Outsourcing (IT/BPOs) companies partnering with DCT providers. Further investments include analytics-driven tools for razor-sharp Healthcare Professional (HCP) profiling and targeting, and the use of automation tools in areas such as Adverse Events (AE) intakes to rapidly evolve with the market needs. In this research, we present a detailed assessment of 28 operations service providers featured on the Life Sciences Operations Services PEAK Matrix®. We provide a relative positioning and analysis of the providers’ market shares, along with our evaluation of their strengths and limitations. This report will enable enterprises to identify suitable service providers to manage the evolving needs of their businesses. Scope Industry: life sciences BPS Geography: global The assessment is based on Everest Group’s annual RFI process for calendar year 2023, interactions with leading life sciences operations service providers, client reference checks, and an ongoing analysis of the life sciences operations market. Contents This report provides a detailed analysis of 28 operations service providers and includes: Relative positioning of the providers on Everest Group’s PEAK Matrix® for Life Sciences Operations Services Comparison of the providers’ capabilities and market shares Everest Group’s analysis of the providers’ strengths and limitations Membership(s) Life Sciences Business Process Sourcing and Vendor Management

Everest Group’s Life Sciences Sales and Marketing Operations – Service Provider Compendium 2023 provides comprehensive and fact-based snapshots of 17 life sciences sales and marketing service providers. It offers a detailed profile of each provider, with a comprehensive picture of its company overview, key leaders, scale of operations, recent developments and investments, partnerships, technology solutions and capabilities, talent initiatives, delivery locations, scope of services, and portfolio mix. Each profile also specifies the provider’s position on Everest Group’s PEAK Matrix® and offers an insightful analysis of its capabilities. The compendium will enable providers to benchmark themselves against their competitors, while buyers will be able to assess the providers based on the desired set of capabilities. Scope Industry: life sciences Geography: North America Contents In this research, we feature 17 life sciences sales and marketing operations service provider profiles and include: Service suite and scale of operations: key leaders, service suites, FTEs, revenue, recent developments, and partnerships Delivery locations: city-level detail of key delivery locations worldwide Capabilities and clients: major engagements, revenue by process coverage, revenue by geography, revenue by buyer size, and revenue by line of business Proprietary solutions and partnerships:brief descriptions of key life sciences sales and marketing technology solutions and partnerships Everest Group assessment:includes providers’ position on Everest Group’s PEAK Matrix®, along with their strengths and limitations Membership(s) Life Sciences Business Process Sourcing and Vendor Management

The life sciences industry has always been resilient against global macroeconomic, geopolitical, and regulatory changes. With the onset of COVID-19 and the spiraling demand for vaccines, the clinical trials and R&D spend of top biopharmas have been bullish. Enterprises have adopted innovative ways of conducting clinical trials (such as decentralized clinical trials). The regulators have also evolved with the changing times by adopting virtual/hybrid audits to meet the demand for daily doses. The latest macroeconomic trends such as rising inflation and high interest rates have had a significant impact on the life sciences industry. The ongoing Russia-Ukraine war has compounded recessionary concerns. The US, in particular, faces further tests with the implementation of Inflation Reduction Act (IRA). Additionally, the pharmaceutical industry is expected to lose billions in the coming years due to impending patent cliffs. Scope: Industry: life sciences BPS Geography: global Contents: This report provides a detailed analysis life sciences landscape and includes: The deteriorating global macro-economic trends and the impact on the life sciences industry Expected impact of the ongoing Russia-Ukraine war The impact of IRA and patent cliffs The implications for the life sciences industry Membership(s) Life Sciences Business Process Sourcing and Vendor Management

The life sciences industry is currently facing several challenges that are significantly impacting drug and device manufacturing costs. In addition to these rising costs, regulatory developments such as the Inflation Reduction Act 2023 and upcoming patent cliffs are further exacerbating the situation. As a result, it has become imperative for life sciences enterprises to establish robust sales and marketing operations to remain competitive. Additionally, the increasing involvement of end-consumers/patients in their healthcare decisions, coupled with evolving Healthcare Practitioner (HCP) needs, has compelled life sciences enterprises to explore the use of digital tools and technologies to enhance their market positioning and ensure continued engagement with their stakeholders. To effectively meet these evolving enterprise needs, providers are revamping their sales and marketing operations offerings. They are investing in a range of solutions, from point analytics such as HCP segmentation to large-scale multi-tower platform solutions covering marketing, promotion, and sales, along with investments in evolving technologies such as the metaverse for sales rep training. In this report, we assess 17 providers featured on Everest Group’s Life Sciences Sales and Marketing Operations – Services PEAK Matrix®. Each profile provides a comprehensive overview of the provider’s service focus, key Intellectual Property (IP) / solutions and domain investments. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other. Scope Industry: life sciences Geography: global The assessment is based on Everest Group’s annual RFI process for calendar year 2022, interactions with leading life sciences providers, client reference checks, and an ongoing analysis of the life sciences market Contents This report features 17 life sciences sales and marketing operations service provider profiles and includes: Providers’ position on Everest Group’s PEAK Matrix® for Life Sciences Sales and Marketing Operations Comparison of the providers’ capabilities and market shares Providers’ key strengths and limitations Membership(s) Life Sciences Business Process Sourcing and Vendor Management

Labeling and artwork are vital components of the life sciences industry, as they ensure regulatory compliance and can be used in packaging, online, and in the supply chain. Failure to comply with Good Manufacturing Practice (GMP) requirements, which include proofreading and change control, can lead to errors in labeling content, resulting in significant fines and drug recalls. In this viewpoint, we examine the evolving labeling and artwork landscape for the biopharmaceutical and medical device industries, current market trends, and the provider landscape, along with possible synergies. Industry Life Sciences BPS Geography Global Contents In this report, we examine: The evolving labeling and artwork landscape for biopharma and medical devices industries Current market trends The provider landscape and possible synergies Membership (s) Life Sciences Business Process Sourcing and Vendor Management

The rising burden of chronic diseases worldwide is driving life sciences companies’ drug development efforts. These drug development efforts need to abide by the strict drug safety regulations of public health organizations, such as the US Federal Drug Administration (FDA) and the European Medicines Agency (EMA). The regulatory protocols mandate the prior- and post-marketing safety assessment of drugs and are increasingly pressing biopharma and medical device companies to effectively capture, assess, and monitor Adverse Events (AEs) to gain the trust of both regulators and consumers. In this viewpoint, we focus on the challenges that face the US$19 billion Pharmacovigilance (PV) market amid increasing AEs and changing regulations. We also look at the measures that life sciences enterprises have adopted in tackling these challenges, including partnering with third-party providers for technology solutions. Industry Life Sciences BPS Geography Global Contents This report provides a detailed analysis of the PV landscape, including: Emerging challenges for life sciences enterprises Enterprise adoption of point solutions The role of third-party providers Current state of the PV market Membership (s) Life Sciences Business Process Sourcing and Vendor Management